Evidence map›Paper›PMID 40291937›Full record

ReviewJournal of medicine and life2025

A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches.

Rand Redwan Al Sari, Husna Irfan Thalib, Syeda Sobiah Imad, Sariya Khan, Shyma Haidar, Bayan Mohammed Khair Al Zoabi, Sahar Hamed Fadda, Samratul Fuadah, Hassan Abu Alwan, Abdullah Alghobaishi

Abstract readReviewComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of medicine and life, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Novel advanced patient-derivedFrontiers in neurology
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rand Redwan Al SariDepartment of General Medicine and Surgery, Batterjee Medical College, Jeddah, Saudi Arabia.
Husna Irfan ThalibDepartment of General Medicine and Surgery, Batterjee Medical College, Jeddah, Saudi Arabia.
Syeda Sobiah ImadDepartment of Medicine and Surgery, AlFaisal University, Riyadh, Saudi Arabia.
Sariya KhanDepartment of General Medicine and Surgery, Batterjee Medical College, Jeddah, Saudi Arabia.
Shyma HaidarDepartment of General Medicine and Surgery, Batterjee Medical College, Jeddah, Saudi Arabia.
Bayan Mohammed Khair Al ZoabiDepartment of General Medicine and Surgery, Batterjee Medical College, Jeddah, Saudi Arabia.
Sahar Hamed FaddaDepartment of General Medicine and Surgery, Batterjee Medical College, Jeddah, Saudi Arabia.
Samratul FuadahDepartment of General Medicine and Surgery, Batterjee Medical College, Jeddah, Saudi Arabia.
Hassan Abu AlwanDepartment of General Medicine Practice and Surgery, King Khalid University, Abha, Saudi Arabia.
Abdullah AlghobaishiKing Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurotransmitters play important roles in brain function, influencing cognition, movement, and behavior. Disruption in neurotransmitter biosynthesis, expression, transport, or function due to genetic mutations can lead to various neurological and psychiatric disorders with variable age of onset. Catecholamines like dopamine, norepinephrine, epinephrine, and serotonin are key monoamines transported by specific transporters, including the dopamine transporter (DAT) and the vesicular monoamine transporter 2 (VMAT2). Disorders that involve monoamine neurotransmitter transport include dopamine transporter deficiency syndrome (DTDS) and brain dopamine-serotonin vesicular disorders (PKDYS2). These rare syndromes manifest with movement disorders and neuropsychiatric symptoms. DTDS results from a mutation in the

Indexed as

Biogenic MonoaminesDopamine Plasma Membrane Transport ProteinsNeurotransmitter AgentsDopamineHumansMutationSerotoninSerotonin Plasma Membrane Transport ProteinsVesicular Monoamine Transport ProteinsBiogenic MonoaminesDopamineDopamine Plasma Membrane Transport ProteinsNeurotransmitter AgentsSerotoninSerotonin Plasma Membrane Transport ProteinsSLC18A2 protein, humanVesicular Monoamine Transport Proteins5-HIAA, 5-Hydroxyindoleacetic AcidAADC, Aromatic L-Amino Acid DecarboxylaseCSF, Cerebrospinal FluidDA, DopamineDAT, Dopamine Transporterdopamine transporterDTDSDTDS, Dopamine Transporter Deficiency SyndromeEEG, ElectroencephalographyENMG, Electroneuromyography and Nerve Conduction StudiesGAT-1, Gamma-Aminobutyric Acid (GABA) Transporter 1HVA, Homovanillic AcidMAO-A, Monoamine Oxidase AMAO-B, Monoamine Oxidase Bmonoamine neurotransmitter transportersNE, NorepinephrinePKDYS1, Infantile-Onset Parkinsonism Dystonia 1PKDYS2PKDYS2, Infantile-Onset Parkinsonism Dystonia 2SNP, Single Nucleotide PolymorphismVMAT2, Vesicular Monoamine Transporter 2WES, Whole Exome Sequencing

Identifiers

PMID40291937
PMCPMC12022732

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.